-
Something wrong with this record ?
Olfactory Outcomes With Dupilumab in Chronic Rhinosinusitis With Nasal Polyps
J. Mullol, C. Bachert, N. Amin, M. Desrosiers, PW. Hellings, JK. Han, R. Jankowski, J. Vodicka, P. Gevaert, N. Daizadeh, AH. Khan, S. Kamat, N. Patel, NMH. Graham, M. Ruddy, H. Staudinger, LP. Mannent
Language English Country United States
Document type Journal Article, Randomized Controlled Trial
- MeSH
- Chronic Disease MeSH
- Smell MeSH
- Adult MeSH
- Antibodies, Monoclonal, Humanized MeSH
- Quality of Life MeSH
- Humans MeSH
- Nasal Polyps * complications drug therapy surgery MeSH
- Rhinitis * drug therapy MeSH
- Sinusitis * drug therapy MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Publication type
- Journal Article MeSH
- Randomized Controlled Trial MeSH
BACKGROUND: Loss of smell (LoS) is one of the most troublesome and difficult-to-treat symptoms of severe chronic rhinosinusitis with nasal polyps (CRSwNP). OBJECTIVE: To assess the impact of dupilumab on sense of smell in severe CRSwNP. METHODS: In the randomized SINUS-24 and SINUS-52 studies, adults with severe CRSwNP received dupilumab 300 mg subcutaneously or matching placebo every 2 weeks for 24 or 52 weeks, respectively. Smell was assessed using daily patient-reported LoS score (0-3) and University of Pennsylvania Smell Identification Test (UPSIT; 0-40). Data from the 2 studies were pooled through week 24. Relationships between patient phenotypes and smell outcomes were also assessed. RESULTS: We randomized 724 patients (286 placebo, 438 dupilumab); mean CRSwNP duration was 11 years; 63% had prior sinonasal surgery. Mean baseline LoS was 2.74. Dupilumab produced rapid improvement in LoS, evident by day 3, which improved progressively throughout the study periods (least squares mean difference vs placebo -0.07 [95% CI -0.12 to -0.02]; nominal P < .05 at day 3, and -1.04 [-1.17 to -0.91]; P < .0001 at week 24). Dupilumab improved mean UPSIT by 10.54 (least squares mean difference vs placebo 10.57 [9.40-11.74]; P < .0001) at week 24 from baseline (score 13.90). Improvements were unaffected by CRSwNP duration, prior sinonasal surgery, or comorbid asthma and/or nonsteroidal anti-inflammatory drug-exacerbated respiratory disease. Baseline olfaction scores correlated with all measured local and systemic type 2 inflammatory markers except serum total immunoglobulin E. CONCLUSIONS: Dupilumab produced rapid and sustained improvement in sense of smell, alleviating a cardinal symptom of severe CRSwNP.
Centre de recherche du Centre hospitalier de l'Université de Montreal Montreal Quebec Canada
Eastern Virginia Medical School Norfolk Va
Faculty of Health Studies University of Pardubice Pardubice Czech Republic
Ghent University Ghent Belgium
Hospital Clínic IDIBAPS Universitat de Barcelona CIBERES Barcelona Catalonia Spain
Karolinska Institutet Stockholm Sweden
Regeneron Pharmaceuticals Inc Tarrytown NY
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22018987
- 003
- CZ-PrNML
- 005
- 20241024114248.0
- 007
- ta
- 008
- 220720s2022 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jaip.2021.09.037 $2 doi
- 035 __
- $a (PubMed)34628065
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Mullol, Joaquim $u Hospital Clínic-IDIBAPS, Universitat de Barcelona, CIBERES, Barcelona, Catalonia, Spain. Electronic address: JMULLOL@clinic.cat
- 245 10
- $a Olfactory Outcomes With Dupilumab in Chronic Rhinosinusitis With Nasal Polyps / $c J. Mullol, C. Bachert, N. Amin, M. Desrosiers, PW. Hellings, JK. Han, R. Jankowski, J. Vodicka, P. Gevaert, N. Daizadeh, AH. Khan, S. Kamat, N. Patel, NMH. Graham, M. Ruddy, H. Staudinger, LP. Mannent
- 520 9_
- $a BACKGROUND: Loss of smell (LoS) is one of the most troublesome and difficult-to-treat symptoms of severe chronic rhinosinusitis with nasal polyps (CRSwNP). OBJECTIVE: To assess the impact of dupilumab on sense of smell in severe CRSwNP. METHODS: In the randomized SINUS-24 and SINUS-52 studies, adults with severe CRSwNP received dupilumab 300 mg subcutaneously or matching placebo every 2 weeks for 24 or 52 weeks, respectively. Smell was assessed using daily patient-reported LoS score (0-3) and University of Pennsylvania Smell Identification Test (UPSIT; 0-40). Data from the 2 studies were pooled through week 24. Relationships between patient phenotypes and smell outcomes were also assessed. RESULTS: We randomized 724 patients (286 placebo, 438 dupilumab); mean CRSwNP duration was 11 years; 63% had prior sinonasal surgery. Mean baseline LoS was 2.74. Dupilumab produced rapid improvement in LoS, evident by day 3, which improved progressively throughout the study periods (least squares mean difference vs placebo -0.07 [95% CI -0.12 to -0.02]; nominal P < .05 at day 3, and -1.04 [-1.17 to -0.91]; P < .0001 at week 24). Dupilumab improved mean UPSIT by 10.54 (least squares mean difference vs placebo 10.57 [9.40-11.74]; P < .0001) at week 24 from baseline (score 13.90). Improvements were unaffected by CRSwNP duration, prior sinonasal surgery, or comorbid asthma and/or nonsteroidal anti-inflammatory drug-exacerbated respiratory disease. Baseline olfaction scores correlated with all measured local and systemic type 2 inflammatory markers except serum total immunoglobulin E. CONCLUSIONS: Dupilumab produced rapid and sustained improvement in sense of smell, alleviating a cardinal symptom of severe CRSwNP.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a humanizované monoklonální protilátky $7 D061067
- 650 _2
- $a chronická nemoc $7 D002908
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a nosní polypy $x komplikace $x farmakoterapie $x chirurgie $7 D009298
- 650 _2
- $a kvalita života $7 D011788
- 650 12
- $a rýma $x farmakoterapie $7 D012220
- 650 12
- $a sinusitida $x farmakoterapie $7 D012852
- 650 _2
- $a čich $7 D012903
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 700 1_
- $a Bachert, Claus $u Ghent University, Ghent, Belgium; Karolinska Institutet, Stockholm, Sweden
- 700 1_
- $a Amin, Nikhil $u Regeneron Pharmaceuticals, Inc., Tarrytown, NY
- 700 1_
- $a Desrosiers, Martin $u Centre de recherche du Centre hospitalier de l'Université de Montreal (CRCHUM), Montreal, Quebec, Canada
- 700 1_
- $a Hellings, Peter W $u University Hospitals Leuven, Leuven, Belgium
- 700 1_
- $a Han, Joseph K. $u Eastern Virginia Medical School, Norfolk, Va $7 xx0324318
- 700 1_
- $a Jankowski, Roger $u Université de Lorraine, ORL CHRU de Nancy, Nancy, France
- 700 1_
- $a Vodicka, Jan $u Faculty of Health Studies, University of Pardubice, Pardubice, Czech Republic
- 700 1_
- $a Gevaert, Philippe $u Ghent University, Ghent, Belgium
- 700 1_
- $a Daizadeh, Nadia $u Sanofi, Cambridge, Mass
- 700 1_
- $a Khan, Asif H $u Sanofi, Chilly-Mazarin, France
- 700 1_
- $a Kamat, Siddhesh $u Regeneron Pharmaceuticals, Inc., Tarrytown, NY
- 700 1_
- $a Patel, Naimish $u Sanofi, Bridgewater, NJ
- 700 1_
- $a Graham, Neil M H $u Regeneron Pharmaceuticals, Inc., Tarrytown, NY
- 700 1_
- $a Ruddy, Marcella $u Regeneron Pharmaceuticals, Inc., Tarrytown, NY
- 700 1_
- $a Staudinger, Heribert $u Sanofi, Bridgewater, NJ
- 700 1_
- $a Mannent, Leda P $u Sanofi, Chilly-Mazarin, France
- 773 0_
- $w MED00201300 $t The journal of allergy and clinical immunology. In practice $x 2213-2201 $g Roč. 10, č. 4 (2022), s. 1086-1095.e5
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34628065 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20241024114242 $b ABA008
- 999 __
- $a ok $b bmc $g 1822543 $s 1170230
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 10 $c 4 $d 1086-1095.e5 $e 20211007 $i 2213-2201 $m The journal of allergy and clinical immunology. In practice $n J Allergy Clin Immunol Pract $x MED00201300
- LZP __
- $a Pubmed-20220720
